Does China require animal testing for imported cosmetics?

Few regulatory questions cause more confusion — and more concern — for international beauty brands entering the Chinese market than the issue of animal testing. For years, the answer was a straightforward and unavoidable “yes.” Every imported cosmetic product, no matter how well-established in its home market, had to undergo animal testing before it could be legally sold in China. That landscape has shifted dramatically and continues to evolve. As of 2026, the answer is far more nuanced: China no longer requires animal testing for the vast majority of imported ordinary cosmetics, but important exceptions and requirements remain. This article provides a comprehensive, authoritative breakdown of the current regulatory framework so that foreign brands can plan their market entry strategy with confidence.

What was the pre-2021 animal testing requirement?

For decades, China’s cosmetics regulations mandated that all imported cosmetics — regardless of their safety record or history of use in other countries — undergo animal testing before receiving approval for sale. This requirement was enshrined in the Cosmetics Hygiene Supervision Regulations and enforced by what was then the China Food and Drug Administration (CFDA). The rationale was straightforward: Chinese regulators required in vivo (live animal) toxicology data to assess product safety, believing that no foreign regulatory approval could substitute for locally conducted testing.

The practical impact on global beauty brands was severe. International companies faced an ethical dilemma: either forego the world’s second-largest beauty market (projected at over 600 billion RMB by 2025–2026) or compromise their cruelty-free commitments. Many brands opted for the latter, quietly conducting animal tests to access China’s rapidly growing consumer base. Others, particularly independent “clean beauty” and cruelty-free brands, avoided the market entirely. Industry estimates from the period suggest that China’s animal testing requirement directly excluded roughly 15–20% of global cosmetic brands from competing in the market.

The pre-2021 regime applied uniformly to all imported cosmetics. Both “ordinary” products (moisturizers, cleansers, shampoos, makeup) and “special-use” products (sunscreens, hair dyes, anti-hair-loss products, freckle removers, deodorants) were subject to the same mandatory animal testing protocols. The tests typically included acute oral toxicity, skin and eye irritation, skin sensitization, and sometimes repeated-dose toxicity studies conducted on rabbits, guinea pigs, and mice.

What changed in May 2021?

The landmark reform arrived on May 1, 2021, when China implemented its updated Regulations on the Supervision and Administration of Cosmetics (CSAR), together with supporting implementation rules. This regulatory overhaul represented the most significant shift in Chinese cosmetics law in over three decades. The centerpiece of the reform for animal testing was the introduction of Article 9 of the Implementation Regulations, which explicitly exempted certain imported ordinary cosmetics from mandatory animal testing.

Under the new framework, imported ordinary cosmetics can enter the Chinese market through a filing (record-keeping) process rather than a full registration process — and the filing pathway does not require animal testing data. This change brought China into closer alignment with international regulatory norms, including those of the European Union, which has banned animal testing for cosmetics since 2013.

It is critical for brands to understand that this exemption is not automatic. To qualify, the imported product must meet three specific conditions:

• Classification as ordinary cosmetics: The product cannot make any claims that would classify it as a “special cosmetic” under Chinese law.
• No use by children under 12: Products intended for infants, toddlers, or children (including baby lotions, baby shampoos, and children’s sunscreens) remain ineligible for the exemption and still require animal testing data.
• All ingredients must be listed in the IECIC: Every ingredient in the product formulation must appear in the 已使用化妆品原料目录 (Inventory of Existing Cosmetic Ingredients in China, or IECIC). If a formulation contains any new ingredient not yet listed in the IECIC, animal testing data may still be required.

How do ordinary cosmetics differ from special cosmetics?

China’s regulatory framework divides all cosmetic products into two categories, and this classification is the single most important determinant of whether animal testing is required.

Ordinary cosmetics (普通化妆品) encompass the vast majority of beauty and personal care products. This category includes facial cleansers, toners, moisturizers, serums, eye creams, body lotions, shampoos, conditioners, body washes, makeup products (foundation, lipstick, eyeshadow, mascara), fragrances, and nail care products. As of 2026, these products qualify for the filing pathway and are exempt from animal testing provided the three conditions above are met.

Special cosmetics (特殊化妆品) are defined by regulation as products with specific functional claims. The list includes sunscreens and sunscreen-containing products, hair dyes, permanent wave products, anti-hair-loss products, hair-growth products, freckle-removal and whitening products, and deodorants. Products making claims related to these functions — even if the primary function of the product is cosmetic — will be classified as special cosmetics. For special cosmetics, the registration pathway remains mandatory, and animal testing data has historically been required.

However, as discussed below, even this boundary has begun to shift in 2023–2026.

What is the ‘免于动物测试’ policy?

The phrase 免于动物测试 (miǎn yú dòngwù cèshì) translates directly to “exempt from animal testing.” This is the official Chinese regulatory term for the exemption policy. It appears in NMPA guidance documents and on the official Cosmetics Registration and Filing Information Service Platform. When a product qualifies for this exemption, the NMPA system will mark it accordingly, and no animal testing data need be submitted as part of the filing dossier.

It is important to note that the exemption applies to the submission requirement — brands are not required to conduct animal tests. However, the NMPA still expects robust safety data. This is where alternative testing methods come into play.

What alternative testing methods are accepted?

China has made significant progress in accepting and even promoting non-animal alternative testing methods. The National Medical Products Administration (NMPA) has published a list of accepted alternative test methods, many of which align with OECD guidelines and international standards. As of 2026, the following alternative methods are recognized:

• In vitro testing: Cell-based assays to assess skin irritation, eye irritation (e.g., the bovine corneal opacity and permeability test, BCOP), skin corrosion, and phototoxicity. These methods use reconstructed human cells rather than live animals.
• Reconstructed 3D skin models: China has approved several commercial 3D human skin equivalent models (such as EpiSkin and EpiDerm) for testing skin corrosion and irritation. These models use human-derived cells grown to mimic the structure of human skin. Chinese laboratories now commonly offer testing using these models, and the NMPA officially recognizes the results.
• Computer-based toxicology: In silico methods using quantitative structure-activity relationship (QSAR) models and read-across approaches are increasingly accepted for predicting toxicity based on chemical structure similarity to known safe ingredients. The NMPA has issued guidance on acceptable in silico approaches.
• Human repeat-insult patch tests (HRIPT): While not strictly an “alternative” method, human volunteer testing for skin sensitization is accepted as a substitute for animal-based sensitization tests in many cases.
• Bacterial reverse mutation tests (Ames test): This in vitro genotoxicity test is widely accepted and does not involve animals.

China’s Center for Drug Evaluation (CDE) and the NMPA have been actively participating in international harmonization efforts through the International Cooperation on Cosmetics Regulation (ICCR) and the International Council for Harmonisation (ICH). The trend is clearly toward broader acceptance of alternatives and eventual alignment with regions that have fully banned animal testing.

What about the 2023–2024 expanded exemptions?

In late 2023 and continuing through 2024, the NMPA issued a series of incremental expansions to the animal testing exemption. The most notable change was the pilot program covering certain special cosmetics manufactured in specific regions, including the Hainan Free Trade Port and the Guangdong-Hong Kong-Macao Greater Bay Area. Under these pilots, certain special cosmetics (notably sunscreen products with ingredients already established in the IECIC) could qualify for a streamlined registration process that did not require new animal testing data, provided the product had already been approved in a recognized mature regulatory jurisdiction such as the EU, the United States, Japan, or South Korea.

In 2024, the NMPA further clarified that special cosmetics that contain only ingredients already listed in the IECIC and have no new safety concerns could, in certain cases, use alternative data packages instead of full animal testing. While this does not amount to a complete exemption for all special cosmetics, it signals the regulator’s direction of travel. As of early 2026, industry observers expect further liberalization, with some predicting that by 2027–2028, China may fully exempt all cosmetics — including special cosmetics — from mandatory animal testing, provided adequate alternative safety data is available.

What is the IECIC and why does it matter?

The 已使用化妆品原料目录 (Inventory of Existing Cosmetic Ingredients in China, IECIC) is the official list of cosmetic ingredients that have been historically used in China and are therefore considered “existing” substances. For imported cosmetics seeking exemption from animal testing via the filing pathway, every single ingredient in the product formulation must be present in the most current version of the IECIC.

As of 2026, the IECIC contains approximately 8,800 entries. This is a substantial list but by no means exhaustive. Many novel ingredients — particularly those used in cutting-edge cosmeceuticals, biotechnology-derived actives, or emerging “clean beauty” formulations — may not yet be listed. If even one ingredient is absent from the IECIC, the product may be reclassified as requiring a full safety data package that includes animal testing data.

Brands should therefore conduct a thorough IECIC review during the product formulation stage, ideally before finalizing any product intended for the Chinese market. If a desired ingredient is not in the IECIC, brands may either reformulate or pursue a new ingredient registration — a longer and more expensive process.

How are global beauty brands navigating this landscape?

Major multinational beauty conglomerates have been at the forefront of adapting to China’s evolving regulatory environment. L’Oréal, which has operated in China since 1997, has publicly supported the move away from animal testing and has invested heavily in alternative testing infrastructure. The company operates a dedicated research and innovation center in Shanghai that focuses on developing and validating alternative methods. L’Oréal was among the first to submit products through the post-2021 filing pathway without animal testing data.

Estée Lauder, another industry leader, has similarly adapted its China strategy. The company worked closely with Chinese testing laboratories to validate alternative methods and has successfully filed numerous ordinary cosmetics through the exemption pathway. For its special cosmetics lines (including its popular sunscreen products), Estée Lauder has pursued both the traditional registration route with animal testing data where required and, more recently, the expanded exemption pilot programs in Hainan and the Greater Bay Area.

Smaller and independent brands face a steeper learning curve. The cost and complexity of regulatory compliance — including IECIC review, safety assessment report preparation, alternative testing, and navigating the filing platform — can be significant for brands without dedicated regulatory affairs teams. However, a growing ecosystem of Chinese regulatory consulting firms now offers turnkey services specifically designed to help international brands navigate the animal testing exemption, making market entry more accessible than ever before.

Notably, brands that are fully committed to a cruelty-free positioning (including those certified by organizations such as Leaping Bunny or PETA) have found that the post-2021 framework allows them to enter the Chinese market for the first time. Brands such as The Body Shop, which previously avoided China due to its animal testing policies, have been able to begin market entry preparations under the new regime. However, these brands must carefully manage their claims: the exemption applies only to products that meet all conditions, and any misclassification or non-compliant claim could trigger full registration requirements.

What practical steps should brands take?

For a foreign beauty brand preparing to enter China in 2026, the recommended path to take advantage of the animal testing exemption is as follows:

1. Determine product classification: Work with a regulatory expert to confirm whether each product is “ordinary” or “special” under Chinese law. Be especially careful with products that make functional claims — marketing language alone can trigger reclassification.
2. Audit your ingredient list against the IECIC: Obtain the most current version of the IECIC and check every ingredient. Any ingredient not on the list requires either reformulation or a separate new-ingredient registration process.
3. Ensure no claims target children under 12: Products labeled or marketed for infants, toddlers, or children are ineligible for the exemption, regardless of their ingredient profile.
4. Prepare alternative safety data: Even if animal testing is not required, you will need a comprehensive safety assessment report. This should include data from in vitro tests, 3D skin model studies, in silico predictions, and human patch tests where applicable.
5. Appoint a Chinese responsible person: All imported cosmetic products must have a designated Chinese responsible person (either a local subsidiary or an authorized representative licensed in China) who bears legal responsibility for product safety and compliance.
6. Submit through the filing platform: File the product via the NMPA’s Cosmetics Registration and Filing Information Service Platform. The filing process for ordinary cosmetics typically takes 2–5 working days for an acknowledgment, with the product becoming legally marketable upon filing completion.
7. Maintain post-market compliance: Remember that the exemption applies to market entry, not ongoing oversight. Brands remain subject to post-market surveillance, adverse event reporting, and potential random testing by provincial drug administrations.

Conclusion: What does the future hold?

The trajectory of China’s animal testing policy is unequivocally toward liberalization. The May 2021 reform was not an endpoint but a beginning. Since then, the NMPA has progressively expanded exemptions, accepted a wider range of alternative methods, and signaled its intent to align more closely with international standards. The rapid growth of China’s domestic beauty industry — now the world’s second-largest — has created powerful economic incentives for the regulator to remove barriers to innovation and market access.

For foreign beauty brands, the message is clear: the animal testing barrier that once made entering China incompatible with a cruelty-free commitment has been substantially, if not yet completely, dismantled. Brands with ordinary cosmetics that use IECIC-listed ingredients can enter without animal testing. Brands with special cosmetics face more complex requirements but have an expanding set of options, including pilot programs and alternative data acceptance. The strategic question for most brands in 2026 is no longer “Can we enter China without animal testing?” but rather “How do we optimally structure our product portfolio and regulatory approach to maximize the exemption opportunities available today?”

China’s animal testing landscape will almost certainly continue to evolve. Brands that invest now in understanding the regulatory framework, building relationships with qualified Chinese testing labs and consultants, and preparing comprehensive alternative safety dossiers will be best positioned to capitalize on what remains one of the world’s most dynamic and rewarding beauty markets. Is your brand ready to take the next step toward China market entry without compromising its cruelty-free commitments?